Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹181.64
3.84 (2.16%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹877 Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
33.4
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹107+69.8%
52W High₹219-17.1%
Current Price
₹181.64
Circuit Limits (5%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹172.56
Upper Circuit₹190.72
Reference Price
₹181.64
Investment Checklist
Double Bottom on 1D (BREAKOUT CONFIRMED) — target ₹174.94
Rounding Bottom on 1W — target ₹305.54
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA(20) Crossover: Price crossed above EMA(20): Fresh bullish momentum signal.
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
49%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
179.97
EMA50
166.83
EMA200
157.73
Price Action
DOWNTREND
BEARISH
Higher Highs0
Higher Lows3
Lower Highs8
Lower Lows6
Support & Resistance Levels
Resistance (Above)
₹186.42
₹191.38
₹212.58
₹219.00
Support (Below)
₹181.14
₹175.48
₹173.00
₹170.08
₹165.12
Volume Analysis
TrendDECREASING
Change-94.80%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹179.82
3% Risk₹176.19
5% Risk₹172.56
7% Risk (Custom)
₹168.93Technical Levels
1x ATR (Volatility)₹171.11
2x ATR (Swing)₹160.58
3x ATR (Trend)₹150.05
Immediate Support₹181.14
Moving Averages
EMA 20 (Medium-term)₹179.97
EMA 50 (Trend)₹166.83
EMA 200 (Long-term)₹157.73
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹172.4 Cr | ₹135.2 Cr | ₹117.9 Cr | ₹194.3 Cr |
| Net Profit | ₹9.7 Cr | ₹7.4 Cr | ₹-9.9 Cr | ₹9.3 Cr |
| EPS | — | ₹1.54 | ₹-2.06 | ₹1.93 |
| Operating Profit | ₹20.3 Cr | ₹16.7 Cr | ₹-5.3 Cr | ₹17.8 Cr |
ROE
7.44%
ROCE
8.96%
Debt/Equity
0.29
Current Ratio
1.76
OPM
9.18%
NPM
4.81%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 04 Sept 2025 | Dividend - Rs 3 Per Share | DIVIDEND |
| 02 Sept 2024 | Annual General Meeting/Dividend - Rs 3 Per Share | AGM |
| 07 Sept 2023 | Annual General Meeting/Dividend - Rs 3 Per Share | AGM |
| 04 Aug 2022 | Dividend - Rs 3 Per Share | DIVIDEND |
| 05 Aug 2021 | Dividend - Rs 1.50 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for KOPRAN
View AllNEWS
positive
Business Standard - Markets 24d ago
Kopran consolidated net profit rises 94.94% in the March 2026 quarter
Sales rise 35.77% to Rs 234.02 crore
KOPRANHealthcare
positive
ET Markets - Stocks 62d ago
Madhusudan Kela picks beaten-down smallcap bets; buys Indiabulls, Simplex Infra in Q4
Ace investor Madhusudan Kela has bought stakes in Indiabulls Limited and Simplex Infrastructures Limited. These companies have seen recent underperformance. Kela's move signals a contrarian investment strategy. His portfolio includes other companies like Kopran and Bombay Dyeing. This selective accumulation in beaten-down stocks is a key highlight.
ACEBFINVESTBOMDYEINGIBULLSLTDINFRAKOPRANMADHUSUDANSIMPLEXINFSMALLCAPCapital GoodsConstruction